Abstract
Transcatheter aortic valve implantation (TAVI) has been accepted as one of primary options for treatment of symptomatic severe aortic stenosis. Although TAVI has been predominantly used for patients at high risk or with old age who were not considered optimal candidates for surgical aortic valve replacement (SAVR), its indication is now expanding toward low risk profile and younger age. Many clinical trials are now ongoing to test the possibility of TAVI for use in patients even with uncharted indications who are not eligible for SAVR in current guidelines but may benefit from valve replacement. Current issues including periprocedural safety, long-term adverse events, hemodynamics and durability associated with TAVI should be also solved for expanding use of TAVI. The review presents current status and future directions of TAVI and discusses perspectives in Korea.
Original language | English |
---|---|
Pages (from-to) | 283-297 |
Number of pages | 15 |
Journal | Korean Circulation Journal |
Volume | 49 |
Issue number | 4 |
DOIs | |
Publication status | Published - 2019 |
Bibliographical note
Publisher Copyright:© 2019 Korean Society of Circulation. All rights reserved.
All Science Journal Classification (ASJC) codes
- Internal Medicine
- Cardiology and Cardiovascular Medicine